Financings in Brief: LifeCell
This article was originally published in The Gray Sheet
Executive Summary
LifeCell: Tissue repair company raises approximately $16 mil. from a Dec. 1 secondary offering of 4.0 mil. shares at $4.50 per share. The Woodlands, Texas-based firm's initial plans had also included the sale of 500,000 shares by selling shareholders ("The Gray Sheet" Oct. 20, p. 18). Proceeds are tabbed for further development, sales and marketing of its AlloDerm acellular dermal graft product, as well as for working capital and general corporate purposes. Underwriters Vector Securities International and Gruntal & Co. hold an overallotment option for 600,000 shares being offered by selling shareholders...
You may also be interested in...
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.
Medtronic Launches Remote Live-Stream Surgery, New AI Capabilities
Medtronic will launch a new feature that allows for live streaming of surgical procedures in more than 20 countries and the addition of 14 AI-driven algorithms to enhance surgical workflow.
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.